Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Setting a benchmark for resource utilization and quality of care in patients undergoing transcatheter aortic valve implantation in Europe-Rationale and design of the international BENCHMARK registry

G. McCalmont, E. Durand, S. Lauck, DF. Muir, MS. Spence, M. Vasa-Nicotera, D. Wood, F. Saia, N. Chatel, CM. Lüske, J. Kurucova, P. Bramlage, D. Frank

. 2021 ; 44 (10) : 1344-1353. [pub] 20210909

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003550

Grantová podpora
N/A Edwards Lifesciences

BACKGROUND: The use of transcatheter aortic valve implantation (TAVI) for treating aortic stenosis (AS) has increased exponentially in recent years. Despite the availability of clinical practice guidelines for the management of valvular heart disease, disparities in quality of care (QoC) for TAVI patients remain widespread across Europe. Tailored QoC measures will help to reduce resource utilization and improve patient outcomes without compromising patient safety. Using a clear set of QoC measures, the BENCHMARK registry aims to document the progress that can be achieved if such tailored QoC measures are implemented. METHODS: The BENCHMARK registry (BENCHMARK) is a non-interventional, multicenter registry in patients with severe symptomatic AS undergoing TAVI with a 1- and 12-months follow-up. BENCHMARK will be conducted at 30 centers across Europe and will enroll a total of 2400 consecutive TAVI patients. Patients suffering from severe symptomatic AS who undergo TAVI with a balloon-expandable transcatheter aortic valve will be included. The registry will comprise four phases: (1) a retrospective baseline evaluation phase; (2) an education phase; (3) an implementation phase; and (4) a prospective effect documentation phase (prospective phase). The registry's primary objectives are to reduce the length of hospital stay and accelerate the post-procedural patient recovery pathway, but without compromising safety. The study started in April 2021 and has an estimated completion date of May 2023. DISCUSSION: BENCHMARK will establish QoC measures to reduce resource utilization, intensive care unit bed occupancy, and overall length of hospitalization with uncompromised patient safety post-TAVI (ClinicalTrials.gov Identifier: NCT04579445).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003550
003      
CZ-PrNML
005      
20220127150118.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/clc.23711 $2 doi
035    __
$a (PubMed)34499383
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a McCalmont, Gemma $u Cardiology Department, James Cook University Hospital, Middlesbrough, UK
245    10
$a Setting a benchmark for resource utilization and quality of care in patients undergoing transcatheter aortic valve implantation in Europe-Rationale and design of the international BENCHMARK registry / $c G. McCalmont, E. Durand, S. Lauck, DF. Muir, MS. Spence, M. Vasa-Nicotera, D. Wood, F. Saia, N. Chatel, CM. Lüske, J. Kurucova, P. Bramlage, D. Frank
520    9_
$a BACKGROUND: The use of transcatheter aortic valve implantation (TAVI) for treating aortic stenosis (AS) has increased exponentially in recent years. Despite the availability of clinical practice guidelines for the management of valvular heart disease, disparities in quality of care (QoC) for TAVI patients remain widespread across Europe. Tailored QoC measures will help to reduce resource utilization and improve patient outcomes without compromising patient safety. Using a clear set of QoC measures, the BENCHMARK registry aims to document the progress that can be achieved if such tailored QoC measures are implemented. METHODS: The BENCHMARK registry (BENCHMARK) is a non-interventional, multicenter registry in patients with severe symptomatic AS undergoing TAVI with a 1- and 12-months follow-up. BENCHMARK will be conducted at 30 centers across Europe and will enroll a total of 2400 consecutive TAVI patients. Patients suffering from severe symptomatic AS who undergo TAVI with a balloon-expandable transcatheter aortic valve will be included. The registry will comprise four phases: (1) a retrospective baseline evaluation phase; (2) an education phase; (3) an implementation phase; and (4) a prospective effect documentation phase (prospective phase). The registry's primary objectives are to reduce the length of hospital stay and accelerate the post-procedural patient recovery pathway, but without compromising safety. The study started in April 2021 and has an estimated completion date of May 2023. DISCUSSION: BENCHMARK will establish QoC measures to reduce resource utilization, intensive care unit bed occupancy, and overall length of hospitalization with uncompromised patient safety post-TAVI (ClinicalTrials.gov Identifier: NCT04579445).
650    _2
$a aortální chlopeň $x chirurgie $7 D001021
650    12
$a aortální stenóza $x chirurgie $7 D001024
650    _2
$a benchmarking $7 D019985
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a časové faktory $7 D013997
650    12
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $7 D065467
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Durand, Eric $u Department of Cardiology, FHU CARNAVAL, Normandie University, UNIROUEN, Rouen, France
700    1_
$a Lauck, Sandra $u Center for Heart Valve Innovation, St Paul's Hospital, University of Vancouver, Vancouver, British Columbia, Canada
700    1_
$a Muir, Douglas F $u Cardiology Department, James Cook University Hospital, Middlesbrough, UK
700    1_
$a Spence, Mark S $u Cardiology Department, Royal Victoria Hospital, Belfast, UK
700    1_
$a Vasa-Nicotera, Mariuca $u Cardiology Department, Frankfurt University, Frankfurt, Germany
700    1_
$a Wood, David $u Center for Heart Valve Innovation, St Paul's Hospital, University of Vancouver, Vancouver, British Columbia, Canada
700    1_
$a Saia, Francesco $u Department of Cardiology, University of Bologna, Bologna, Italy
700    1_
$a Chatel, Nicolas $u Edwards Lifesciences, Nyon, Switzerland
700    1_
$a Lüske, Claudia M $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
700    1_
$a Kurucova, Jana $u Edwards Lifesciences, Prague, Czech Republic
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
700    1_
$a Frank, Derk $u Department of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), University Clinical Center Schleswig-Holstein (UKSH), Kiel, Germany $u German Center for Cardiovascular Research, partner site Hamburg/Kiel/Lübeck, Kiel, Germany
773    0_
$w MED00001122 $t Clinical cardiology $x 1932-8737 $g Roč. 44, č. 10 (2021), s. 1344-1353
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34499383 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150114 $b ABA008
999    __
$a ok $b bmc $g 1751112 $s 1154699
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 44 $c 10 $d 1344-1353 $e 20210909 $i 1932-8737 $m Clinical cardiology $n Clin Cardiol $x MED00001122
GRA    __
$a N/A $p Edwards Lifesciences
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace